Hypertension, inhibitors of the renin angiotensin system and Covid-19

Grant number: COV/GLA/20/04

Grant search

Key facts

  • Disease

    COVID-19
  • Known Financial Commitments (USD)

    $99,009.04
  • Funder

    CSO Scotland
  • Principal Investigator

    Rhain Touyz
  • Research Location

    United Kingdom
  • Lead Research Institution

    University of Glasgow
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

There is a lot of coverage in the media that certain drugs to treat high blood pressure (hypertension) may worsen COVID-19. However, there is no clinical evidence to support this and there is much confusion for both patients and doctors. Many patients are stopping their hypertension medication, which is dangerous as this could lead to severe heart disease and even death. Our study will examine if hypertensive patients have more severe COVID-19 than patients who do not have pre-existing hypertension. We will also assess if certain blood pressure drugs aggravate or improve infection. This is especially important in Scotland where the rate of hypertension is high. Our study will provide information to guide doctors and patients in the coming months as we treat COVID.

Publicationslinked via Europe PMC

Last Updated:14 hours ago

View all publications at Europe PMC

ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease.